SCHEMBL5708669

SCHEMBL5708669

O=Cc1cccc(CCc2nc(C3CCC3)cs2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
ADRB1 P08588 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
PTGS1 P23219 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36
DRD5 P21918 1/20 0.36
DRD3 P35462 1/20 0.36
HDAC1 Q13547 4/20 0.35
HDAC6 Q9UBN7 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7477308 0.81 GRM2 (0.43) SMN1; SMN2HDAC1HDAC6CCR5ECE1
SCHEMBL5708660 0.80 DRD2 (0.40) ALDH1A1MAPTDRD2DRD3HDAC1
SCHEMBL5708655 0.79 MAOA (0.47) KDM4EMEN1ALDH1A1TP53ADRB1
SCHEMBL5708664 0.75 MAOA (0.48) TP53MAPTMAOAMAOB
SCHEMBL8653482 0.74 HDAC1 (0.30) HDAC1HDAC6
SCHEMBL9263854 0.73 ALDH1A1 (0.55) KDM4EMEN1ALDH1A1TP53ADRB1
SCHEMBL9263846 0.73 ALDH1A1 (0.55) KDM4EMEN1ALDH1A1TP53ADRB1
SCHEMBL5908275 0.72 METTL3 (0.33) ALDH1A1HDAC1HDAC6CCR5
SCHEMBL20171376 0.68 RAB9A (0.51) MEN1ALDH1A1TP53MAPTHPGD
SCHEMBL5020713 0.67 MAOA (0.56) ALDH1A1CYP3A4MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0999209-B1 2-SULFAMOYLBENZOIC ACID DERIVATIVES KAKEN PHARMA CO LTD (JP) 2006-11-02 EP disclosed
US-20020049228-A1 2-Sulfamoylbenzoic acid derivatives KAKEN PHARMACEUTICALS 2002-04-25 US disclosed
US-6376671-B1 LEUKOTRIENE AND THROMBOXANE A2 ANTAGONISTIC AGENTS; ANTIALLERGIC AGENTS KAKEN PHARMACEUTICAL CO., LTD. (JP) 2002-04-23 US disclosed
US-6255321-B1 ANTIALLERGENS; RESPIRATRORY SYSTEM DISORDERS KAKEN PHARMACEUTICAL CO., LTD. (JP) 2001-07-03 US disclosed
EP-0999209-A1 2-SULFAMOYLBENZOIC ACID DERIVATIVES KAKEN PHARMACEUTICAL CO., LTD. (JP) 2000-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049228-A1 2-Sulfamoylbenzoic acid derivatives LTB4R2, LTB4R, CYSLTR2 KDM4E 3733/4885MEN1 3704/4885ALDH1A1 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.